نتائج البحث

Synergistic Treatment Approach for Pulmonary Fibrosis: Prednisone and Cyclophosphamide Regulation of Circular RNA MORF4L1 and MicroRNA-29a-3p Targeting BRD4.

• Authors : Wang D; Department of Rheumatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China. .; Zhao H

Subjects: MicroRNAs*/MicroRNAs*/MicroRNAs*/genetics ; Pulmonary Fibrosis*/Pulmonary Fibrosis*/Pulmonary Fibrosis*/genetics ; Pulmonary Fibrosis*/Pulmonary Fibrosis*/Pulmonary Fibrosis*/drug therapy

• Source: Iranian journal of allergy, asthma, and immunology [Iran J Allergy Asthma Immunol] 2024 Jul 27; Vol. 23 (4), pp. 437-451. Date of Electronic Publication: 2024 Jul 27.Publisher: Tehran University of Medical Sciences Country of Publication: Iran NLM ID: 101146178 Publication Model: Electronic Cited Medium: Internet

تفاصيل العنوان

Prediction model of male reproductive function damage caused by CHOP chemotherapy regimen for non-Hodgkin's lymphoma.

• Authors : Zhang J; Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an City, Shanxi Province, 710049, China.; Department of Hematology, The First Affiliated Hospital of Xiamen University, Xiamen City, Fujian Province, 361000, China.

Subjects: Cyclophosphamide*/Cyclophosphamide*/Cyclophosphamide*/adverse effects ; Cyclophosphamide*/Cyclophosphamide*/Cyclophosphamide*/administration & dosage ; Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/Lymphoma, Non-Hodgkin*/drug therapy CHOP protocol

• Source: BMC cancer [BMC Cancer] 2024 Nov 12; Vol. 24 (1), pp. 1391. Date of Electronic Publication: 2024 Nov 12.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Characterizing the Cell-Free Transcriptome in a Humanized Diffuse Large B-Cell Lymphoma Patient-Derived Tumor Xenograft Model for RNA-Based Liquid Biopsy in a Preclinical Setting.

• Authors : Decruyenaere P; Department of Hematology, Ghent University Hospital, 9000 Ghent, Belgium.; OncoRNALab, Cancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/genetics ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/pathology ; Cyclophosphamide*

• Source: International journal of molecular sciences [Int J Mol Sci] 2024 Sep 16; Vol. 25 (18). Date of Electronic Publication: 2024 Sep 16.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

تفاصيل العنوان

Metabolic tumour area: a novel prognostic indicator based on 18 F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era.

• Authors : Cui S; Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.; Institute of Clinical Translation of Nuclear Medicine and Molecular Imaging, Soochow University, Changzhou, Jiangsu, China.

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/mortality

• Source: BMC cancer [BMC Cancer] 2024 Jul 25; Vol. 24 (1), pp. 895. Date of Electronic Publication: 2024 Jul 25.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.

• Authors : Deng R; Genentech, Inc., South San Francisco, California, USA.; Gibiansky L

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Doxorubicin*/Doxorubicin*/Doxorubicin*/pharmacokinetics ; Doxorubicin*/Doxorubicin*/Doxorubicin*/analogs & derivatives

• Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jun; Vol. 13 (6), pp. 1055-1066. Date of Electronic Publication: 2024 Apr 15.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.

• Authors : Kwak K; Division of Hematology-Oncology, Department of Internal Medicine, Korea University College of Medicine, 73, Goryeodae-Ro, Seongbuk-Gu, Seoul, 02841, Republic of Korea.; Park Y

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

• Source: Scientific reports [Sci Rep] 2024 May 16; Vol. 14 (1), pp. 11229. Date of Electronic Publication: 2024 May 16.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

[Abdominal obstruction revealing colonic lymphoma: a case report].

• Authors : Zioui M; Service d'Hématologie et Greffe de Moelle, Centre Hospitalier Universitaire Mohammed VI, Faculté de Médecine et de Pharmacie, Université Cadi Ayyad, Marrakech, Maroc.; Lahlimi FE

Subjects: Intestinal Obstruction*/Intestinal Obstruction*/Intestinal Obstruction*/etiology ; Intestinal Obstruction*/Intestinal Obstruction*/Intestinal Obstruction*/diagnosis ; Intestinal Obstruction*/Intestinal Obstruction*/Intestinal Obstruction*/surgery

• Source: The Pan African medical journal [Pan Afr Med J] 2024 Apr 29; Vol. 47, pp. 219. Date of Electronic Publication: 2024 Apr 29 (Print Publication: 2024).Publisher: African Field Epidemiology Network Country of Publication: Uganda NLM ID: 101517926 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

Drug-induced pneumonitis risk in diffuse large B-cell/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.

• Authors : Kaprio E; Faculty of Health Medicine, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.; Prusila R

Subjects: Rituximab*/Rituximab*/Rituximab*/adverse effects ; Rituximab*/Rituximab*/Rituximab*/therapeutic use ; Rituximab*/Rituximab*/Rituximab*/administration & dosage

• Source: Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (1), pp. e6898. Date of Electronic Publication: 2024 Jan 01.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival.

• Authors : Zhang WR; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC); Collaborative Innovation Center for Cancer Medicine, Beijing, China.

Subjects: Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/mortality ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use

• Source: Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (1), pp. e6899. Date of Electronic Publication: 2024 Jan 05.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

تفاصيل العنوان

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

• Source: A Phase Ib Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and

تفاصيل العنوان